Images List Premium Download Classic

Cirrhosis

Cirrhosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
The Scripps Research Institute
August 03, 2017 - N°20170217963

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, ...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Methods and compositions for diagnosis of inflammatory liver disease
Medizinische Hochschule Hannover
June 01, 2017 - N°20170153251

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15. These levels can be used to facilitate ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
May 18, 2017 - N°20170135973

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Urea compounds and their use as enzyme inhibitors
Industry-academic Cooperation Foundation, Yonsei University
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
"methods for modeling hepatic inflammation"
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
March 23, 2017 - N°20170083683

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, ...
Diagnosis of liver fibrosis or cirrhosis
Centre Hospitalier Universitaire D'angers
March 23, 2017 - N°20170082603

This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one marker from a blood test and of at least one data issued from a physical method ...
Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Centre Hospitalier Universitaire D'angers
March 16, 2017 - N°20170071968

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Ultrapure tetrahydrocannabinol-11-oic-acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071900

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071899

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071898

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
The Trustess Of The University Of Pennsylvania
January 26, 2017 - N°20170021037

Non-viral delivery systems comprising engineered hotc dna and rna sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hotc for treatment of liver fibrosis and/or cirrhosis in otcd patients by administering hotc.
Compositions and methods for treating renal failure
La Jolla Pharmaceutical Company
January 19, 2017 - N°20170014471

The present disclosure relates to the use of angiotensin ii in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals Inc.
December 22, 2016 - N°20160367518

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post ...
Nitrogenous heterocyclic derivatives and their application in drugs
Sunshine Lake Pharma Co., Ltd.
December 08, 2016 - N°20160355501

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially ...
Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
Sunshine Lake Pharma Co., Ltd.
December 08, 2016 - N°20160354387

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
November 24, 2016 - N°20160338982

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of preparing the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
September 29, 2016 - N°20160279157

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Loading